Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi

Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi, is a new report which provides an in-depth analysis of three technological innovations that are being heralded to revolutionize the drug discovery process by rapidly expediting drug discovery research. This report focuses on lab-on-a-chip (LOC) devices, nanotechnology and RNA interference drug discovery technologies that are increasingly being used to identify novel drug targets and to successfully reduce R&D timelines. This report also provides: in-depth analysis of the market forces, current and future technological advances, detailed company profiles, eight year forecasts of market size for LOC devices, nanotechnology in, drug discovery and RNA interference technologies and therapeutics. Incorporate the most innovative technologies into your drug discovery process, significantly reduce R&D timelines and build a unique competitive edge with the help of this latest report.
[Cerrar las informaciones del articulo de mercado]

Emerging Drug Discovery Technologies
Executive Summary
Introduction
Lab-on-a-chip/microfluidics
Nanotechnology
RNA interference

Chapter 1 Introduction

Summary
Overview
A historical overview of the drug discovery process
Drug discovery in the 1950s and 1960s
Drug discovery in the 1980s
Drug discovery today
Emerging drug discovery technologies
Lab-on-a-chip/microfluidic technologies
Nanotechnology
RNA interference
Report objectives

Chapter 2 Lab-on-a-chip/microfluidics

Summary
Introduction
LOC technologies
LOC design issues
Microarrays
Spotted microarrays
In situ fabricated arrays
DNA applications
Protein applications
The LabChip
Lab-on-a-CD
Chip-based electrospray system for mass spectroscopy
HPLC-on-a-chip
Microfluidic PCR
Multiplexed capillary electrophoresis
Market drivers and restraints
Market drivers
HTS
Reduction of human error
Reduced exposure to hazardous materials
Reduction in sample requirement and routine tasks
Cost savings
Market restraints
Reduction in demand
Reluctance to replace old systems with new technologies
Market analysis
Competitive structure
Market share
Aclara BioSciences
Advion BioSciences, Inc.
Agilent Technologies
BioMicro Systems
BioTrove Inc.
Caliper Life Sciences
Cepheid
CombiMatrix Corp.
Eksigent Technologies
Epigem Limited
Fluidigm Corp.
Gyros AB
Nanogen
Nanostream Inc.
Protiveris
Sequenom
Zyomyx
Future developments

Chapter 3 Nanotechnology

Summary
Introduction
Nanotechnologies
Applications
Drug discovery and drug delivery
Biosensing
Other applications
Public opinion
Funding
Market
Nano-enabled drug discovery tools
Atomic force microscopy
Nano-mass spectroscopy
Dip-pen nanolithography
Nanoarrays
Nanoparticles for drug discovery
Quantum dots and gold nanoparticles
Nanoshells
Nanobarcode particles
Nano-enabled drugs
Abraxane
RenaZorb
Antimicrobial emulsions
Antioxidants and fullerenes
Industry challenges
High demands of drug discovery applications
Long-term stability of nanomaterials
Technical issues in nano-assembly and molecular manufacturing
Barriers to collaborations
Lack of test standardization
Scalability
Pharmaceutical companies reluctant to invest in nanotechnology
Funding for nanotechnology
Market drivers and restraints
Market drivers
Technological drivers
Increased funding
Social and economic factors
Market restraints
Uncertainty
Public awareness
Environmental concerns
Detection of incurable diseases
Large expectations
Market analysis
Competitive structure
Market share
3DM Inc.
Alnis Biosciences Inc.
American Pharmaceuticals Partners Inc.
BioCrystal Ltd.
BioForce NanoSciences Inc.
CrystalPlex Corp.
C Sixty Inc.
Evident Technologies, Inc.
NanBio Corp.
Nanosphere
PharmaSeq, Inc
Quantum Dot Corp.
Future developments

Chapter 4 RNA interference (RNAi)

Summary
Introduction
Gene silencing
Methods for gene silencing
Aptamers
Ribozymes
Peptide nucleic acid (PNA) and PNA-DNA chimeras
Antisense oligonucleotides
RNA interference (RNAi)
RNAi mechanism
RNAi approaches
siRNA
ddRNAi
MicroRNAs (miRNAs)
Short hairpin RNAs (shRNAs)
Delivery methods
Delivery using chemical transfections
Delivery using electroporation
Delivery using expression vectors
Delivery using cell-penetrating peptides
In vivo delivery of siRNAs
Industry challenges
Intellectual property issues
Off-target effects
Delivery of siRNA in vitro and in vivo
Toxicity issues from RNAi
Pricing issues
Efficacy of RNAi
Standardization of technologies
Proof of therapeutic potential
Market drivers and restraints
Market drivers
Demand for accelerated drug discovery
Resolution of intellectual property issues
Robust, efficient and potent technology
Functional genomics and proteomics studies
Vector-based and siRNA price decline
Reliability
Market restraints
Expensive RNAi reagents
Delivery of siRNA
Failure of antisense drugs
Lack of robust clinical data
Selection and design of appropriate siRNA
Toxicity and off-target effects
Market analysis
Revenue forecasts
Trends by geographic region
North America
Europe
Japan
Rest of the World
Competitive structure
Market share analysis
Ambion
Alnylam Pharmaceuticals, Inc.
Benitec Ltd
CytRx Corp.
Cenix BioScience
Devgen
Dharmacon, Inc.
Eurogentec (EGT)
Imgenex Corp.
Immusol Inc.
Invitrogen Corp.
InvivoGen
MWG Biotech
Proligo
Promega
Qiagen.
Sirna Therapeutics
Future developments

Chapter 5 Appendix

Research methodology and information sources
Primary research methodology
Secondary research methodology
Market sizing
Forecasting
Index
Abbreviations and acronyms
[Cerrar la tabla de contenidos]

Table 2.1: Microfluidics/LOC revenue forecasts, 2005-2012 53
Table 3.2: Nano-enabled drug discovery revenue forecasts, 2004-2012 113
Table 4.3: RNAi revenue forecasts, 2004-2012 162
Table 5.4: Abbreviations and acronyms, A-L 185
Table 5.5: Abbreviations and acronyms, M-Z 186

Figure 1.1: Drug development process during the 1950s and 1960s 19
Figure 1.2: Drug development process during the 1980s 20
Figure 1.3: Drug development process today 21
Figure 2.1: The Gyros Bioaffy lab-on-a-CD 42
Figure 2.2: Advion BioSciences’ ESI Chip 44
Figure 2.3: HPLC-on-a-chip 45
Figure 2.4: Cepheid’s GeneXpert cartridges for PCR analysis 47
Figure 2.5: Market drivers and restraints for LOC/microfluidics devices in drug discovery 49
Figure 2.6: Microfluidics/LOC revenue forecasts, 2005-2012 53
Figure 2.7: Microfluidics/lab-on-a-chip market shares, 2004 54
Figure 3.1: Expression of cells using QDots 94
Figure 3.2: Binding of Nanosphere’s nanoparticle probe to a selected genetic or proteomic target 95
Figure 3.3: Nano-enabled drug discovery industry challenges 102
Figure 3.4: Market drivers and restraints for nano-enabled drug discovery 107
Figure 3.5: Nano-enabled drug discovery revenue forecasts, 2004-2012 114
Figure 3.6: Nanoenabled drug discovery market shares, 2004 116
Figure 4.7: RNAi pathways 143
Figure 4.8: Industry challenges faced by RNAi industry participants 152
Figure 4.9: Market drivers and restraints for RNAi technology 157
Figure 4.10: RNAi revenue forecasts and growth rates, 2004-2012 162
Figure 4.11: RNAi revenues by geographic region, 2004 163
Figure 4.12: RNAi market shares, 2004 166
[Ocultar lista de tablas / figuras]